Cargando…

PK‐tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital

IMPORTANCE: Tertiary prophylaxis using a low‐dose regimen is usually insufficient to prevent recurrent joint bleeding and deterioration in joint diseases in children with severe hemophilia A. Pharmacokinetic (PK) dosing is a useful approach to increase the precision and efficiency of prophylaxis. OB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Peijing, Chen, Zhenping, Cheng, Xiaoling, Wang, Yan, Zhang, Ningning, Zhen, Yingzi, Wu, Xinyi, Wu, Runhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331374/ https://www.ncbi.nlm.nih.gov/pubmed/32851288 http://dx.doi.org/10.1002/ped4.12122

Ejemplares similares

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
por: Ai, Di, et al.
Publicado: (2022)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
por: Wu, Runhui, et al.
Publicado: (2021)

Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates
por: Huang, Kun, et al.
Publicado: (2022)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
por: Chen, Zhenping, et al.
Publicado: (2021)

Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China
por: Li, Zekun, et al.
Publicado: (2019)

Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A
por: Huang, Kun, et al.
Publicado: (2022)

Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors
por: Li, Zekun, et al.
Publicado: (2021)

A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations
por: Li, Zekun, et al.
Publicado: (2020)

Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China
por: Xu, Qian, et al.
Publicado: (2023)

Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient
por: Liu, Guoqing, et al.
Publicado: (2021)

F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China
por: Sun, Jie, et al.
Publicado: (2022)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
por: Sun, Jie, et al.
Publicado: (2022)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B
por: Liu, Guoqing, et al.
Publicado: (2023)

Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A
por: Urasiński, Tomasz, et al.
Publicado: (2023)

T2 mapping in the quantitative evaluation of articular cartilage changes in children with hemophilia: A pilot study
por: Zhang, Ningning, et al.
Publicado: (2019)

Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: A single-center observational study
por: Cheng, Xiaoling, et al.
Publicado: (2019)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
por: Yu, Jacky K., et al.
Publicado: (2019)

Mycoplasma pneumoniae pneumonia associated thrombosis at Beijing Children’s hospital
por: Liu, Jinrong, et al.
Publicado: (2020)

P1662: OPTIMIZED PROPHYLAXIS BASED ON INDIVIDUALIZED TARGET TROUGH FVIII LEVEL IN PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA A
por: Huang, K., et al.
Publicado: (2022)

Correction: Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
por: Moon, Byung Suk, et al.
Publicado: (2013)

Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
por: Stimec, Jennifer, et al.
Publicado: (2021)

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
por: Colombo, Giorgio L, et al.
Publicado: (2011)

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
por: Albattat, Sami, et al.
Publicado: (2023)

Management of Severe Hemophilia A: Low-Dose Prophylaxis vs. On-Demand Treatment
por: Munawar Ali, Rabeea, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
por: Gu, Congling, et al.
Publicado: (2022)

Iranian Low-dose Escalating Prophylaxis Regimen in Children with Severe Hemophilia A and B
por: Eshghi, Peyman, et al.
Publicado: (2017)

Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A
por: Meijón Ortigueira, María del Mar, et al.
Publicado: (2023)

Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban china
por: Wu, Runhui, et al.
Publicado: (2012)

Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries
por: Usuba, Koyo, et al.
Publicado: (2019)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
por: Qvigstad, Christian, et al.
Publicado: (2020)

Clinical profile and demographic characteristics of moderate and severe hemophilia patients in a tertiary care hospital of Bangladesh
por: Islam, Mohammed Nadimul, et al.
Publicado: (2022)

Pharmacokinetics and complementary evaluation system-based guidance on prophylaxis of paediatric patients with haemophilia A in China with Kovaltry: protocol of the LEAP study
por: Kun, Huang, et al.
Publicado: (2021)

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation
por: Bukkems, Laura H., et al.
Publicado: (2023)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A
por: Zhao, Yongqiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rla9v3e2kne642p9svr1lpj71d